IMPEDIMED LIMITED — Capital/Financing Update 2012

Jun 7, 2012

==> picture [109 x 104] intentionally omitted <==

----- Start of picture text -----

ASX: IPD
----- End of picture text -----

8 June 2012

ASX RELEASE: Listing Rule 6.22 – Options and Release of Restricted Shares

Brisbane, Australia - ImpediMed Limited (ASX: IPD) today announced that effective 4 May 2012 in accordance with Listing Rule 6.22, the exercise price for the Quoted Options (IPDO) was reduced from $0.7012 per IPDO to $0.6830 per IPDO.

The exercise price for each of the unquoted options outstanding as of 4 May 2012 was reduced by $0.0182. The unquoted options were issued at various dates with various exercise prices and expiration dates. A summary of outstanding options and revised exercise prices is detailed in the tables below.

Additionally, ImpediMed Limited provides notice of release of 74,000 restricted unquoted fully paid ordinary shares. The restriction on trading will be released 10 business days from the date of this ASX release.

Table 1: Employee Share Option Plans (ESOP)

Number of Options Exercise Price ($) Revised Exercise Price($) Exercisable until	Number of Options Exercise Price ($) Revised Exercise Price($) Exercisable until	Number of Options Exercise Price ($) Revised Exercise Price($) Exercisable until	Number of Options Exercise Price ($) Revised Exercise Price($) Exercisable until
50,000	0.8512 $	0.8330 $	30-Sep-12
101,666	0.6972	0.6790	29-May-12
33,334	0.8512	0.8330	29-Jul-12
16,666	0.8512	0.8330	28-Oct-12
50,000	0.8512	0.8330	23-Nov-12
26,666	0.8512	0.8330	24-Dec-12
101,666	0.6972	0.6790	29-May-13
273,698	0.7159	0.6977	31-Dec-13
101,668	0.6972	0.6790	29-May-14
393,666	0.7798	0.7616	31-Dec-14
273,698	0.7159	0.6977	31-Dec-14
120,000	0.6834	0.6652	31-Dec-14
180,000	0.7798	0.7616	10-Dec-15
393,666	0.7798	0.7616	31-Dec-15
273,704	0.7159	0.6977	31-Dec-15
21,667	0.6600	0.6418	31-Dec-15
120,000	0.6834	0.6652	31-Dec-15
266,667	0.7900	0.7718	31-Dec-15
21,667	0.6600	0.6418	31-Dec-16
20,000	0.6834	0.6652	31-Dec-16
31,667	0.7000	0.6818	31-Dec-16
377,401	0.7798	0.7616	31-Dec-16
446,667	0.7900	0.7718	31-Dec-16
80,000	0.4700 $	0.4518 $	31-Dec-16

Page 1 of 3

Table 1: ESOP (continued)

Number of Options Exercise Price($) Revised Exercise Price($) Exercisable until	Number of Options Exercise Price($) Revised Exercise Price($) Exercisable until	Number of Options Exercise Price($) Revised Exercise Price($) Exercisable until	Number of Options Exercise Price($) Revised Exercise Price($) Exercisable until
229,000	0.4800 $	0.4618 $	31-Dec-16
15,000	0.6000	0.5818	31-Dec-16
15,000	0.6000	0.5818	31-Dec-17
21,666	0.6600	0.6418	31-Dec-17
31,667	0.7000	0.6818	31-Dec-17
266,666	0.7900	0.7718	31-Dec-17
600,000	0.4700	0.4518	30-Jun-17
448,334	0.4800	0.4618	30-Jun-17
10,000	0.6000	0.5818	30-Jun-17
229,000	0.4800	0.4618	31-Dec-17
15,000	0.6000	0.5818	31-Dec-18
31,666	0.7000	0.6818	31-Dec-18
448,335	0.4800	0.4618	30-Jun-18
10,000	0.6000	0.5818	30-Jun-18
228,998	0.4800	0.4618	31-Dec-18
448,333	0.4800	0.4618	30-Jun-19
10,000	0.6000 $	0.5818 $	30-Jun-19

Table 2: CEO options

Number of Options Exercise Price($) Revised Exercise Price($) Exercisable until	Number of Options Exercise Price($) Revised Exercise Price($) Exercisable until	Number of Options Exercise Price($) Revised Exercise Price($) Exercisable until	Number of Options Exercise Price($) Revised Exercise Price($) Exercisable until
166,667	0.8912 $	0.8730 $	17-Oct-12
166,667	1.0112	0.9930	17-Oct-12
249,224	0.6562	0.6380	31-Dec-12
166,667	0.8912	0.8730	17-Oct-13
166,667	1.0112	0.9930	17-Oct-13
249,224	0.6562	0.6380	31-Dec-13
83,333	1.0000	0.9818	30-Jun-14
166,666	0.8912	0.8730	17-Oct-14
166,666	1.0112	0.9930	17-Oct-14
83,333	1.0000	0.9818	31-Dec-14
83,333	1.0000	0.9818	30-Jun-15
83,333	1.0000	0.9818	31-Dec-15
83,334	1.0000	0.9818	30-Jun-16
83,334	1.0000	0.9818	31-Dec-16
26,667	0.6000	0.5818	31-Dec-16
50,000	0.6000	0.5818	30-Jun-17
26,667	0.6000	0.5818	31-Dec-17
50,000	0.6000	0.5818	30-Jun-18
26,666	0.6000	0.5818	31-Dec-18
50,000	0.6000 $	0.5818 $	30-Jun-19

Stephen Denaro Company Secretary

ENDS

Page 2 of 3

For further information contact:

Greg Brown CEO & Director T: +61(7) 3860 3700 M: +61408281127

About ImpediMed

L-Dex[®] is a trademark of ImpediMed Limited.

The L-Dex[®] scale is a tool to aid in the clinical assessment of unilateral lymphoedema of the arm and leg in women and the leg in men by a medical provider. The L-Dex[®] scale is not intended to diagnose or predict lymphoedema of an extremity.

About ImpediMed

ImpediMed Limited is the world leader in the development and distribution of medical devices employing Bioimpedance Spectroscopy (BIS) technologies for use in the non-invasive clinical assessment and monitoring of fluid status. ImpediMed’s primary product range consists of a number of medical devices that aid surgeons, oncologists, therapists and radiation oncologists in the clinical assessment of patients for the potential onset of secondary lymphoedema. Pre-operative clinical assessment in cancer survivors, before the onset of symptoms, may prevent the condition from becoming a lifelong management issue and thus improve the quality of life of the cancer survivor. ImpediMed has the first medical device with an FDA clearance in the United States to aid health care professionals, clinically assess secondary unilateral lymphoedema of the arm and leg in women and the leg in men. For more information, visit: www.impedimed.com.au

Page 3 of 3